Increasing the Number of HIV Diagnostics Test is expected to drive the Growth of the Global HIV Diagnostics Test Market
HIV preventive strategies include
testing and counselling for sexually transmitted infections (STIs) and HIV,
preventing mother-to-child transmission, and using treatments and
antiretroviral medications. The introduction of Point-of-Care (POC) testing for
HIV detection has resulted in the healthcare industry harnessing new advances
in POC devices through research and development. POC devices are simple to use
and maintain, and they may be carried easily. Antiretroviral therapy (ART),
Cluster of Differentiation 4 (CD4) tests, HIV Rapid Diagnostic Tests (RDTs),
Viral Load (VL) testing, and HIV early-infant diagnostic tests have all come
from recent advances in POC testing.
Since the beginning of the
COVID-19 pandemic, the Egyptian government has made enormous investments in
providing health services to all patients, particularly those with chronic
conditions such as AIDS. Furthermore, according to the Ministry of Health Saudi
Arabia, the MoH would spend around US$ 71 billion in 2020 on healthcare
awareness campaigns in Saudi Arabia.
Key market participants are
focused on the development and marketing of technologically enhanced HIV
diagnostics tests in order to grow their product range and worldwide
HIV Diagnostics
Test market presence. For example, F. Hoffmann-La Roche AG, a
Swiss global healthcare business, debuted the Elecsys HIV Duo immunoassay in
the United States in 2020 after receiving FDA approval in April 2020. Elecsys
HIV Duo is the first 4th generation HIV testing system in the United States to
detect HIV p24 antigen and anti-HIV antibodies separately.
Comments
Post a Comment